CD44 and lip and oral cavity carcinoma: CD44-targeted NIR-PIT combined with IL-15 treatment showed superior in vivo therapeutic efficacy to either CD44-targeted NIR-PIT or IL-15 treatment alone in colon, lung, and oral cancer models.